INTRODUCTION
============

The colorectal cancer (CRC) incidence rate increases steadily with age.[@b1-gnl-13-176],[@b2-gnl-13-176] Colonoscopy is widely endorsed as a screening modality to reduce CRC incidence and mortality.[@b3-gnl-13-176]--[@b6-gnl-13-176] Proper bowel preparation is critical for an effective colonoscopy; however, bowel preparations are often considered by patients to be the most burdensome aspect of colonoscopy.[@b7-gnl-13-176]--[@b10-gnl-13-176] Furthermore, age influenced the adequacy of bowel preparation, and poor bowel preparation occurred in up to 57% of elderly patients.[@b11-gnl-13-176]--[@b19-gnl-13-176]

Traditionally, a polyethylene glycol (PEG)-based preparation requires the ingestion of a large volume of liquid. However, the tolerability of a bowel preparation is related to its volume, taste, and adverse effects (which are particularly troublesome in elderly patients). Therefore, low-volume bowel cleansing agents are associated with a greater willingness to undergo repeat colonoscopy.[@b20-gnl-13-176],[@b21-gnl-13-176] A new oral sulfate solution (OSS) formulation with a split-dose regimen has been recently approved as a low-volume regimen.[@b7-gnl-13-176],[@b8-gnl-13-176] Although a few studies have evaluated the efficacy and safety of OSS compared to those of PEG in average risk populations, data specific to the elderly population is lacking.[@b7-gnl-13-176],[@b8-gnl-13-176] Therefore, we conducted a multicenter, prospective, investigator-blinded, randomized, controlled trial (known as the SEE-SAFE study) to investigate the efficacy, safety, and acceptance of the OSS preparation with a split-dose regimen, in comparison to those of a standard PEG preparation, in elderly patients.

MATERIALS AND METHODS
=====================

1. Eligibility criteria
-----------------------

Participants aged 65 to 75 years who were willing to undergo colonoscopy were recruited between June 21, 2016 and July 7, 2017. Exclusion criteria were as follows: history of colorectal surgery; history of congestive heart failure or acute myocardial infarction within 6 months; American Society of Anesthesiologists physical status index \>3; presence of liver cirrhosis, chronic renal failure, inflammatory bowel disease, or severe inflammation; severe constipation (bowel movement \<3 times/week or use of stool softeners); a physical or mental disability that would interfere with participation; or refusal to provide consent. This study was approved by the local institutional review boards of all participating centers and the Institutional Review Board of Kyung Hee University Hospital at Gangdong (KHNMC IRB 2016-03-021). Written informed consent was obtained from all participants.

2. Study design
---------------

The SEE-SAFE study was a non-inferiority, prospective, randomized, investigator-blinded, multicenter study. The study was conducted at nine endoscopy centers in South Korea, and the trial was registered at [Clinicaltrials.gov](http://Clinicaltrials.gov) (identifier NCT03112967). Assignment to the 4-L PEG or OSS arm was determined according to a computer-generated randomization schedule, and participants were randomly allocated in a 1:1 ratio. Blood samples taken at the screening visit and the day of the procedure were analyzed for serum electrolytes (sodium, potassium, chloride, calcium, phosphate, and magnesium), blood urea nitrogen (BUN) level, creatinine level, and estimated glomerular filtration rate (GFR). The GFR was estimated using the Modification of Diet in Renal Disease Study equation (MDRD GFR). Acute kidney injury was defined as a 25% increase in serum creatinine level.[@b22-gnl-13-176]

On the day of the procedure, all participants completed a questionnaire that collected the following information: taste, amount, and feeling sensations of the solution, acceptability, the amount of solution actually taken (complete/incomplete), adverse events (nausea, vomiting, abdominal pain, abdominal distension, fecal incontinence, sleep disturbance, numbness, general weakness, seizure, mental change, thirstiness, dizziness, and tingling sensations), and willingness to repeat the same bowel preparation medication if indicated in the future ([Supplementary Material 1](#s1-gnl-13-176){ref-type="supplementary-material"}). Feeling sensation is defined as the texture of the preparation from intake until swallowing. Satisfaction ratings were given on a visual analog scale (according to a scale from 1 to 10, higher scores denoting greater satisfaction); the patient was asked to place a mark corresponding to their satisfaction level. Tolerability and acceptability were assessed using the questionnaire data on symptoms occurring during preparation and difficulties in complying with the intake of the solution ([Supplementary Material 1](#s1-gnl-13-176){ref-type="supplementary-material"}).

Bowel preparation efficacy was assessed using Boston Bowel Preparation Scale (BBPS) definitions.[@b23-gnl-13-176] In the BBPS, a 10-point (0--9) summation score is used to assess the overall bowel preparation quality, and is based on the evaluation of three segments of the colon (right colon, transverse colon, and left colon) using a 3-point scoring system (0--3; 0=unprepared colon with mucosa not seen because of solid stool, 1=portion of colonic mucosa of the segment seen, but other areas not well seen due to staining, residual stool, and/or opaque liquid, 2=minor amount of residual staining, stool, and/or opaque liquid, but colonic mucosa of the segment seen well, and 3=entire colonic mucosa seen well with no residual staining, stool, or opaque liquid). An adequate bowel preparation was defined as a total BBPS score ≥6 with all segment scores ≥2, and an excellent cleansing was defined as a total score \>7. At the end of the colonoscopy, the endoscopist recorded the examination start time, the use of sedation, cecal intubation, colonic mucosal abnormalities (including aphthous ulcer), and any adverse events.

3. Study preparations
---------------------

All subjects were instructed to start a low-residue diet 48 hours prior to the colonoscopy and were restricted to a clear fluids diet 24 hours the colonoscopy for the bowel preparation. Both bowel preparation solutions were administered using a split-dose regimen. Participants in the 4-L PEG arm ingested the first 2 L between 18:00 and 20:00 on the day before the colonoscopy; the second 2 L was ingested between 07:00 and 09:00 on the day of the colonoscopy. Participants in the OSS arm were instructed to pour one 180-mL bottle of the study medication into a provided 480-mL mixing cup, fill it with water, and drink the entire volume, followed by two additional 480-mL portions of water (between 18:00 and 20:00 on the day before the colonoscopy). The second OSS dose was ingested at approximately 06:00 on the day of the colonoscopy, using the same formulation protocol. In both study arms, the second dose was taken within 4 hours before the scheduled time of the colonoscopy.

4. Outcome assessment
---------------------

The primary outcome measures of the present study were the bowel cleansing efficacy and the secondary outcome measures were the frequency and severity of adverse events, and the acceptability score.

5. Sample size calculation
--------------------------

The sample size required for at least 80% power to detect a 15% group difference in adequate bowel cleansing frequency with a one-sided significance level of 0.025 was estimated, with the assumption that the proportion of adequate bowel cleansing would be approximately 86% for the PEG group.[@b24-gnl-13-176],[@b25-gnl-13-176] Considering an expected dropout rate of 10%, the total number of participants was calculated to be 198.

6. Statistics
-------------

Group differences were evaluated using two-tailed Student t-tests for continuous variables and two-tailed chi-square test or Fisher exact tests for categorical variables. For laboratory data, the statistical significance of the change from baseline was evaluated using paired t-tests. All p-values are two-tailed, and a p-value \<0.05 was considered statistically significant. Statistical analyses were performed using SPSS software version 20.0 (IBM Corp., Armonk, NY, USA).

RESULTS
=======

During the study period, 198 patients were screened, and 193 were finally randomized and analyzed ([Fig. 1](#f1-gnl-13-176){ref-type="fig"}). The median age was 69.0 years (standard deviation, 2.9), and the male-to-female ratio was 0.8:1. The distribution of underlying diseases and the indications for colonoscopy were similar in the two groups ([Table 1](#t1-gnl-13-176){ref-type="table"}).

1. Colon cleansing efficacy
---------------------------

No group differences in overall efficacy were observed, with "adequate" preparations achieved in 95.9% (93/97) and 94.8% (91/96) of patients in the OSS and 4-L PEG groups, respectively (p=0.747) ([Table 2](#t2-gnl-13-176){ref-type="table"}). However, the OSS group had significantly higher cleansing efficacy scores for both the entire colon (7.9±1.3 for OSS vs 7.4±1.3 for 4-L PEG, p=0.010) and the right colon (2.6±0.5 for OSS vs 2.3±0.5 for 4-L PEG, p=0.001). The cleansing scores for the transverse and left colon were comparable between groups.

2. Clinical safety
------------------

The mean intensity for each preparation-related clinical adverse event is shown in [Table 3](#t3-gnl-13-176){ref-type="table"}. Slightly more gastrointestinal complaints were reported in the OSS group than in the 4-L PEG group; however, all symptomatic events including nausea, vomiting, abdominal pain, abdominal distension, and fecal incontinence were rated as mild. In terms of neurologic symptomatic events, a slightly higher sleep disturbance score was observed in the 4-L PEG group than in the OSS group (p=0.864), while the OSS group reported slightly higher thirstiness scores (p=0.358) ([Table 3](#t3-gnl-13-176){ref-type="table"}). In addition, numbness scores were slightly more favorable in the OSS group than in the 4-L PEG group (p=0.434). However, there were no statistically significant group differences. None of the participants experienced seizures or mental changes ([Table 3](#t3-gnl-13-176){ref-type="table"}). None of the participants had a clinically significant need of intervention to manage the adverse events. All patients successfully completed intake of the whole preparation, and the procedure was performed without any problems.

3. Renal and electrolyte safety
-------------------------------

The laboratory profile changes (on the procedure day vs baseline) for both groups are shown in [Table 4](#t4-gnl-13-176){ref-type="table"}. No serious adverse events were observed in the laboratory data. The groups were similar in the proportion of patients who had a ≥25% increase in creatinine relative to their baseline level (2.1% in each group, p=1.000) ([Table 4](#t4-gnl-13-176){ref-type="table"}). In both groups, serum BUN level significantly decreased after the bowel preparation without clinical significance; however, no significant changes were observed in serum creatinine levels ([Table 4](#t4-gnl-13-176){ref-type="table"}). In addition, there were no significant changes in the MDRD GFR (before OSS vs after OSS, 84.4±23.7 mL/min vs 84.9±20.2 mL/min, p=0.744; 4-L PEG, 88.9±24.8 mL/min vs 87.2±22.9 mL/min, p=0.187). In the 4-L PEG group, serum calcium levels significantly decreased from 9.1±0.6 to 9.0±0.5 mg/L after the bowel preparation (p=0.037). Statistically significant changes in serum sodium levels were shown in both groups following bowel preparation without clinical significance (OSS, p=0.021; 4-L PEG, p=0.002). In the OSS group, serum chloride levels significantly decreased from 105.0±10.4 to 102.6±3.4 mmol/L after the bowel preparation (p=0.030). However, there were no clinically significant changes in any patients with changes in laboratory findings. Furthermore, there were no significant changes in serum phosphate, magnesium, and potassium levels following preparation administration in both groups ([Table 4](#t4-gnl-13-176){ref-type="table"}).

4. Acceptability
----------------

The groups did not remarkably differ in taste ratings (p=0.328) ([Table 5](#t5-gnl-13-176){ref-type="table"}); however, the preparation solution was easier to ingest in the OSS group due to its lower volume and higher "good feeling" ratings than in the 4-L PEG group (p\<0.001, p=0.007, respectively). Furthermore, significantly more patients indicated that they would be willing to use the same preparation in any future colonoscopies in the OSS group than in the 4-L PEG group (92.8% vs 67.7%, p\<0.001). In addition, the overall satisfaction scores were significantly higher in the OSS group than in the 4-L PEG group (7.7±1.5 vs 6.8±2.1, p=0.001) ([Table 5](#t5-gnl-13-176){ref-type="table"}).

DISCUSSION
==========

Age has been consistently associated with poor bowel preparation in previous studies, regardless of the type of preparation.[@b26-gnl-13-176]--[@b29-gnl-13-176] A recent systematic review and meta-analysis reported that nearly 20% of patients aged 65 years or older have poor bowel preparation at the time of their colonoscopy.[@b30-gnl-13-176] Therefore, improving bowel preparation in this age group is an important issue. The results of the present investigator-blinded, prospective, multicenter, randomized clinical trial demonstrate that the OSS preparation is not inferior (in terms of efficacy, safety, and tolerability) to the 4-L PEG preparation in elderly patients. This is the first report to specifically analyze the efficacy, safety, and acceptability of the new OSS preparation in elderly individuals, and provide information important to the selection of the proper bowel preparation protocol for this population.

While 4-L PEG is the most commonly used bowel preparation regimen because of its efficacy and safety properties, the main disadvantage, especially for the elderly, is the substantial volume that must be ingested. However, many clinicians are reluctant to prescribe small volume preparations for elderly patients, as elderly patients are more likely to have poor bowel preparation and are more vulnerable to clinical and laboratory adverse events. Although a previous multicenter study in the US (n=136) reported that OSS ingestion more frequently resulted in an excellent preparation compared to 4-L PEG ingestion (71.4% vs 34.3%), the study included only 29 elderly patients (≥65 years old).[@b8-gnl-13-176] In addition, the study design was not fair as the OSS was administered in split regimen, whereas PEG was administered in a non-split regimen.[@b8-gnl-13-176] Thus, the efficacy of the OSS preparation in the elderly population was not well addressed. Of note, the results for the primary efficacy end point in the present study confirmed that, in elderly patients, OSS and 4-L PEG preparations result in similar cleansing efficacy, with "adequate" preparations achieved in 95.5% of OSS patients and 95.2% of 4-L PEG patients. More importantly, we found that the OSS preparation achieved better cleansing scores than the 4-L PEG preparation in the entire and right colon. CRC in elderly patients more often involves the right colon and grows faster than in younger patients.[@b31-gnl-13-176],[@b32-gnl-13-176] However, the cleanliness of the right colon is often unsatisfactory with low volume preparations.[@b33-gnl-13-176],[@b34-gnl-13-176] Thus, the present results add to the literature, suggesting that OSS preparation with a split-dose regimen better prepares the right colon for evaluation and may be more effective in CRC screening in elderly patients than the 4-L PEG preparation.

Theoretically, the osmotic action of the poorly absorbed sulfates and magnesium in the OSS formulation increases the water content of the stool, thus causing watery diarrhea, which can result in volume depletion. Although OSS is considered safe as a bowel purgative based on animal[@b35-gnl-13-176] and young adult human studies,[@b36-gnl-13-176] limited data currently exist regarding the safety of OSS in terms of renal toxicity and electrolyte disturbance, especially in elderly patients who may be more vulnerable to dehydration than younger patients. Accordingly, concerns exist regarding the occurrence of such adverse events during OSS bowel preparation in elderly individuals. However, the present results indicate that the changes in serum creatinine levels and MDRD GFRs after preparation were similar for OSS and 4-L PEG. In the present study, OSS bowel preparation resulted in a statistically significant decrease in serum chloride values; however, these differences were small and no clinically significant complications were reported. In addition, both preparations were associated with clinically insignificant changes in serum BUN and electrolyte profiles. Furthermore, clinical adverse events were not significantly different between the two preparations, and no serious adverse events such as seizure, mental change, or death were reported. These results are also comparable to those reported in previous studies. For example, in a previous US study, the overall and gastrointestinal discomfort scores for OSS with a split-dose regimen were similar to those for 4-L PEG in patients aged 65 years or older.[@b7-gnl-13-176] In addition, Rex *et al*.[@b8-gnl-13-176] reported that there were no differences between OSS and 4-L PEG preparations in terms of treatment-emergent adverse events in the elderly group. Taken together, these results suggest OSS may be considered as an appropriate option for bowel cleansing in elderly patients.

Another noteworthy finding in the present study concerns the acceptability of the OSS preparation. Compared to 4-L PEG, OSS resulted in better scores regarding the sensation of the amount and feeling of the preparation, which can be potential barriers to future colonoscopy acceptance in elderly patients. Further, the overall satisfaction scores were significantly higher with the OSS preparation than with the 4-L PEG preparation, and patients who received the OSS preparation were more likely to be willing to repeat the preparation in the future than were patients who received the 4-L PEG preparation. In summary, the OSS preparation with a split-dose regimen achieves greater bowel cleansing efficacy, with a similar safety profile and acceptability, than a standard regimen of 4-L PEG in elderly patients.

The present study has some limitations that warrant consideration. The preparation quality was evaluated by different endoscopists; thus, inter- or intra-observer differences may have introduced biases. However, previous studies have consistently demonstrated that the BBPS is a reliable measure for preparation quality, with good inter- and intra-observer reliability among physicians,[@b23-gnl-13-176],[@b37-gnl-13-176] further all study investigators reviewed the representative captured images and reached a consensus before study enrollment. to achieve better inter-observer agreement. Another limitation concerns the limited generalizability of the present findings to Western populations given the exclusive recruitment of Asian individuals in the present study. Therefore, further studies with different ethnic populations are needed. In addition, the present study included only elderly patients aged 65 to 75 and our sample size was too small to provide conclusive data on the safety and efficacy of OSS. To confirm these findings, further large-scaled studies with very elderly (≥75 years old) patients are warranted. Finally, unmeasured several confounders including prior experience of bowel preparation that may also contribute to the results.

In conclusion, the present study demonstrates that OSS, a low-volume bowel preparation solution, is efficacious and safe bowel cleansing tool in elderly individuals. Moreover, the use of OSS enables future colonoscopy acceptability in this population. Further studies with larger sample sizes and different ethnic populations are warranted to confirm these results.
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OSS, oral sulfate solution; PEG, polyethylene glycol.](gnl-13-176f1){#f1-gnl-13-176}

###### 

Baseline Characteristics

  Characteristics                                     4-L PEG (n=96)   OSS (n=97)   p-value
  --------------------------------------------------- ---------------- ------------ ---------
  Age, yr                                             69.3±2.9         68.6±2.9     0.094
  Sex                                                                               0.617
   Male                                               46 (47.9)        43 (44.3)    
   Female                                             50 (52.1)        54 (55.7)    
  Body mass index, kg/m^2^                                                          0.345
   ≥25                                                40 (41.7)        34 (35.1)    
   \<25                                               56 (58.3)        63 (64.9)    
  Indication of colonoscopy                                                         0.610
   Screening                                          42 (43.8)        43 (44.3)    
   Surveillance                                       36 (37.5)        31 (32.0)    
   Diagnostic                                         18 (18.7)        23 (23.7)    
  Underlying disease                                                                0.206
   None                                               33 (34.4)        43 (44.3)    
   Ischemic heart disease                             2 (2.1)          2 (2.1)      
   Hypertension                                       29 (30.2)        28 (28.9)    
   Diabetes                                           7 (7.3)          2 (2.1)      
   Hypertension + diabetes                            15 (15.6)        12 (12.4)    
   Dyslipidemia                                       2 (2.1)          3 (3.1)      
   Other[\*](#tfn3-gnl-13-176){ref-type="table-fn"}   8 (8.3)          7 (7.1)      

Data are presented as mean±SD or number (%).

OSS, oral sulfate solution; PEG, polyethylene glycol.

Parkinson disease, cardiac arrhythmia, and carotid artery stenosis.

###### 

Bowel Cleansing Efficacy as Assessed by the Boston Bowel Preparation Scale

  Bowel cleansing                                               OSS         4-L PEG     p-value
  ------------------------------------------------------------- ----------- ----------- ---------
  Boston Bowel Preparation Scale                                                        
  Total                                                         7.9±1.3     7.4±1.3     0.010
   Right colon[\*](#tfn6-gnl-13-176){ref-type="table-fn"}       2.6±0.5     2.3±0.5     0.001
   Transverse colon[†](#tfn7-gnl-13-176){ref-type="table-fn"}   2.7±0.5     2.6±0.5     0.177
   Left colon[‡](#tfn8-gnl-13-176){ref-type="table-fn"}         2.7±0.5     2.6±0.7     0.210
  Primary efficacy success                                                              0.747
   Adequate                                                     93 (95.9)   91 (94.8)   
   Inadequate                                                   4 (4.1)     5 (5.2)     

Data are presented as mean±SD or number (%).

OSS, oral sulfate solution; PEG, polyethylene glycol.

Cecum and ascending colon;

Hepatic flexure, transverse colon, and splenic flexure;

Descending colon, sigmoid colon, and rectum.

###### 

Clinical Safety Profiles

  Clinical adverse events               OSS       4-L PEG   p-value
  ------------------------------------- --------- --------- ---------
  Gastrointestinal event                                    
   Nausea                               0.8±1.9   0.6±1.7   0.358
   Vomiting                             0.1±0.8   0.3±1.3   0.170
   Abdominal pain                       0.7±1.7   0.5±1.7   0.634
   Abdominal distension                 0.7±1.7   0.5±1.7   0.634
   Fecal incontinence                   0.7±1.7   0.5±1.7   0.634
   Aphthous ulceration on colonoscopy   2 (2.1)   1 (1.0)   1.000
  Neurologic event                                          
   Sleep disturbance                    0.5±1.6   0.6±1.7   0.864
   Numbness                             0.0±0.1   0.1±0.5   0.434
   General weakness                     0±0.0     0±0.0     NA
   Seizure                              0±0.0     0±0.0     NA
   Mental change                        0±0.0     0±0.0     NA
   Thirstiness                          0.8±1.9   0.6±1.7   0.358
   Dizziness                            0.0±0.1   0.0±0.1   1.000
   Tingling sensation                   0.0±0.1   0.0±1.1   1.000

Data are presented as mean±SD or number (%).

OSS, oral sulfate solution; PEG, polyethylene glycol; NA, not available.

###### 

Laboratory Safety Profiles

  Variable                   OSS          p-value   4-L PEG                                    
  -------------------------- ------------ --------- ----------- ------- ------------ --------- -----------
  Laboratory results                                                                           
   Renal function profiles                                                                     
    BUN, mg/dL               16.9±5.9     \<0.001   14.5±4.6            14.9±5.0     \<0.001   13.1±3.8
    Creatinine, mg/dL        0.9±0.2      0.205     0.9±0.2             0.9±0.3      0.684     0.9±0.2
    MDRD GFR, mL/min         84.4±23.7    0.744     84.9±20.2           88.9±24.8    0.187     87.2±22.9
    AKI                                             2 (2.1)     1.000                          2 (2.1)
   Electrolyte profiles                                                                        
    Calcium, mg/dL           9.2±0.6      0.502     9.2±0.5             9.1±0.6      0.037     9.0±0.5
    Phosphate, mg/dL         4.0±3.8      0.177     3.5±0.6             3.5±0.5      0.909     3.5±0.5
    Magnesium, mg/dL         2.2±0.2      0.068     2.2±0.2             2.2±0.3      0.490     2.4±2.4
    Sodium, mg/dL            141.3±3.0    0.021     140.4±3.2           140.9±2.4    0.002     141.8±2.5
    Potassium, mmol/L        4.8±4.2      0.829     4.6±3.8             4.7±4.2      0.216     4.2±0.3
    Chloride, mmol/L         105.0±10.4   0.030     102.6±3.4           103.0±10.9   0.285     104.2±2.7

Data are presented as mean±SD or number (%).

OSS, oral sulfate solution; PEG, polyethylene glycol; BUN, blood urea nitrogen; MDRD GFR, Modification of Diet in Renal Disease Study equation for estimated glomerular filtration rate; AKI, acute kidney injury.

###### 

Tolerability and Acceptability of the Preparation Agents

  Acceptability                            OSS          4-L PEG      p-value
  ---------------------------------------- ------------ ------------ ---------
  Satisfaction for the preparation                                   
   Taste                                   6.2±1.9      5.9±2.2      0.328
   Amount                                  7.7±2.1      6.4±2.8      \<0.001
   Feeling                                 6.7±2.1      5.8±2.5      0.007
  Willingness to repeat same preparation                             \<0.001
   Acceptable                              90 (92.8)    65 (67.7)    
   Not acceptable                          7 (7.2)      31 (32.3)    
  Amount of solution actually taken                                  1.000
   Complete                                97 (100.0)   96 (100.0)   
   Incomplete                              0            0            
  Overall satisfaction                     7.7±1.5      6.8±2.1      0.001

Data are presented as mean±SD or number (%).

OSS, oral sulfate solution; PEG, polyethylene glycol.
